Approval · Notice of Compliance 26663 · 2021
PREVACID: Notice of Compliance 26663
Issued September 16, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26663
- Date
- September 16, 2021
- Company
- Takeda Pharmaceuticals America IncCambridge, Massachusetts, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) following an update to the Company Core Data Sheet and response to an Advisement Letter. Update the PM to the 2020 Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREVACID | Not yet assigned | — |
| PREVACID FASTAB | Not yet assigned | — |
Medicinal ingredients
- LANSOPRAZOLE 15 MG per CAP
- LANSOPRAZOLE 30 MG per CAP
- LANSOPRAZOLE 15 MG per TAB
- LANSOPRAZOLE 30 MG per TAB